SCHEMBL14320987

SCHEMBL14320987

c1cncc(-c2cccc(-c3nc(Nc4ccc5cn[nH]c5c4)c4[nH]ncc4n3)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.54
ROCK2 O75116 2/20 0.45
ABCG2 Q9UNQ0 9/20 0.44
SYK P43405 2/20 0.44
ABCB1 P08183 2/20 0.43
MAPT P10636 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
TSHR P16473 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 2/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320502 0.85 FGFR1 (0.48) FGFR1ROCK2ABCG2SYKMAPT
SCHEMBL14321059 0.84 ABCG2 (0.63) ABCG2ABCB1MAPTKDM4EMAPK1
SCHEMBL14320680 0.84 SYK (0.46) ABCG2SYKABCB1MAPTCYP1A2
SCHEMBL17135656 0.82 ROCK2 (0.51) ROCK2ABCG2SYKCYP1A2CYP3A4
SCHEMBL14320390 0.82 ABCG2 (0.53) ROCK2ABCG2SYKABCB1MAPT
SCHEMBL14321208 0.80 PDE5A (0.52) ROCK2ABCG2SYKABCB1MAPT
SCHEMBL15652843 0.80 ABCG2 (0.54) ROCK2ABCG2ABCB1MAPTCYP3A4
SCHEMBL14320810 0.80 ABCG2 (0.39) ROCK2ABCG2SYKABCB1MAPT
SCHEMBL14321376 0.79 SYK (0.57) SYKMAPTCYP1A2MAPK1LMNA
SCHEMBL14320973 0.79 GBA1 (0.49) FGFR1SYKMAPTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK FGFR1 408/4885ROCK2 80/4885ABCG2 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.